Riyanka Kumari
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Riyanka Kumari has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
- Nitish Kamble
Department of Neurology, National Institute of Mental Health & Neurosciences, Karnataka, India
7 shared publications - Pramod Kumar Pal
Department of Neurology, National Institute of Mental Health & Neurosciences, Karnataka, India
7 shared publications - Babylakshmi Muthusamy
Institute of Bioinformatics, International Technology Park, Bangalore, India
6 shared publications - Ravi Yadav
Department of Neurology, National Institute of Mental Health and Neurosciences (NIMHANS), Bengaluru, India
6 shared publications - Vikram Venkappayya Holla
Department of Neurology, National Institute of Mental Health & Neurosciences, Karnataka, India
6 shared publications - Debjyoti Dhar
Department of Neurology, National Institute of Mental Health and Neurosciences, Bengaluru, India
4 shared publications
Latest Publications
- Open Access
- 25 June 2026
- Published by Elsevier in SSRN Electronic Journal
Generation of a CRISPR/Cas9-corrected Isogenic Control iPSC Line (NIMHi001-A-1) from a Parkinson's Disease Patient-Derived iPSC Line Carrying the LRRK2 I1371V Mutation
We report NIMHi001-A-1, a CRISPR/Cas9-corrected isogenic iPSC line derived from a patient line carrying a heterozygous LRRK2 missense mutation (chr12:40702420A>G; p.Ile1371Val) associated with familial Parkinson's disease. Sanger sequencing confirmed successful correction. The line retained iPSC morphology and expressed pluripotency markers (OCT4, NANOG, SOX2, TRA-1-60, SSEA4) by immunofluorescence, gene expression analysis, and flow cytometry. Normal karyotype (46, XY) and complete genetic identity with the parental line were established by STR profiling. No off-target modifications were detected. The line demonstrated trilineage differentiation potential and tested mycoplasma-negative, providing an isogenic platform to investigate LRRK2 I1371V-specific pathomechanisms and evaluate therapeutic strategies.
- 25 June 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessGeneration of a CRISPR/Cas9-corrected Isogenic Control iPSC Line (NIMHi001-A-1) from a Parkinson's Disease Patient-Derived iPSC Line Carrying the LRRK2 I1371V Mutation
We report NIMHi001-A-1, a CRISPR/Cas9-corrected isogenic iPSC line derived from a patient line carrying a heterozygous LRRK2 missense mutation (chr12:40702420A>G; p.Ile1371Val) associated with familial Parkinson's disease. Sanger sequencing confirmed successful correction. The line retained iPSC morphology and expressed pluripotency markers (OCT4, NANOG, SOX2, TRA-1-60, SSEA4) by immunofluorescence, gene expression analysis, and flow cytometry. Normal karyotype (46, XY) and complete genetic identity with the parental line were established by STR profiling. No off-target modifications were detected. The line demonstrated trilineage differentiation potential and tested mycoplasma-negative, providing an isogenic platform to investigate LRRK2 I1371V-specific pathomechanisms and evaluate therapeutic strategies.
- Open Access
- 5 March 2026
- Published by Ubiquity Press, Ltd. in Tremor and Other Hyperkinetic Movements
- Vol. 16 (1) , 15
Clinical, Radiological, and Genetic Profile of Patients with FA2H-Associated Neurodegeneration: Eight Cases from India and a Review of the Literature
Background: Autosomal recessive spastic paraplegia 35 (SPG35), also known as Fatty acid hydroxylase-associated neurodegeneration (FAHN), is a rare recessive neurodegenerative disorder with or without ataxia, dystonia, and other neurological findings. It is caused by genetic variants in FA2H, which encodes fatty acid 2-hydroxylase. Objective: To report the clinical, electrophysiological, radiological, and genetic profile of patients diagnosed with FAHN. Methods: We performed a retrospective chart review of genetically proven cases of FAHN from our database. Results: We identified eight patients (6 females) with genetically proven FAHN. All patients presented with first-decade onset pyramidal syndrome with or without ataxia and with radiological findings of callosal atrophy, peri-ventricular white matter hyperintensity, and cerebellar atrophy. Iron accumulation was observed in four of them. Whole exome sequencing revealed seven unique variants including three missense variants (c.83G>C;p.Arg28Pro, c.130C>A;p.Pro44Thr, and c.703C>T;p.Arg235Cys), a stop-gain variant (c.379C>T;p.Arg127Ter), a frameshift deletion variant (c.536delT;p.Leu179Argfs*62), a in-frame deletion variant (c.200_202del;p.His67del) and a in-frame duplication variant (c.86_97dup;p.Arg29_Arg32dup). The variants p.Pro44Thr, p.Arg28Pro, p.Arg29_Arg32dup, and p.His67del are located in the iron-binding region, and the p.Arg235Cys in the hydroxylase domain. The other two variants, p.Arg127Ter and p.Leu179Argfs*62, predictively cause protein truncation, leading to loss of the transmembrane domain and the fatty acid hydroxylase domain, which in turn may result in disruption of fatty acid alpha-hydroxylase activity of FA2H. Conclusion: Our study identifies novel variants associated with FA2H in FAHN patients, highlighting their possible roles in iron binding and in the loss of the transmembrane and catalytic domains.
- 5 March 2026
- Published by Ubiquity Press, Ltd. in Tremor and Other Hyperkinetic Movements
- Vol. 16 (1) , 15
Open AccessClinical, Radiological, and Genetic Profile of Patients with FA2H-Associated Neurodegeneration: Eight Cases from India and a Review of the Literature
Background: Autosomal recessive spastic paraplegia 35 (SPG35), also known as Fatty acid hydroxylase-associated neurodegeneration (FAHN), is a rare recessive neurodegenerative disorder with or without ataxia, dystonia, and other neurological findings. It is caused by genetic variants in FA2H, which encodes fatty acid 2-hydroxylase. Objective: To report the clinical, electrophysiological, radiological, and genetic profile of patients diagnosed with FAHN. Methods: We performed a retrospective chart review of genetically proven cases of FAHN from our database. Results: We identified eight patients (6 females) with genetically proven FAHN. All patients presented with first-decade onset pyramidal syndrome with or without ataxia and with radiological findings of callosal atrophy, peri-ventricular white matter hyperintensity, and cerebellar atrophy. Iron accumulation was observed in four of them. Whole exome sequencing revealed seven unique variants including three missense variants (c.83G>C;p.Arg28Pro, c.130C>A;p.Pro44Thr, and c.703C>T;p.Arg235Cys), a stop-gain variant (c.379C>T;p.Arg127Ter), a frameshift deletion variant (c.536delT;p.Leu179Argfs*62), a in-frame deletion variant (c.200_202del;p.His67del) and a in-frame duplication variant (c.86_97dup;p.Arg29_Arg32dup). The variants p.Pro44Thr, p.Arg28Pro, p.Arg29_Arg32dup, and p.His67del are located in the iron-binding region, and the p.Arg235Cys in the hydroxylase domain. The other two variants, p.Arg127Ter and p.Leu179Argfs*62, predictively cause protein truncation, leading to loss of the transmembrane domain and the fatty acid hydroxylase domain, which in turn may result in disruption of fatty acid alpha-hydroxylase activity of FA2H. Conclusion: Our study identifies novel variants associated with FA2H in FAHN patients, highlighting their possible roles in iron binding and in the loss of the transmembrane and catalytic domains.
- Open Access
- 21 August 2024
- Published by Ubiquity Press, Ltd. in Tremor and Other Hyperkinetic Movements
- Vol. 14 (1) , 41
The Clinical, Radiological and Genetic Spectrum of PLA2G6-Associated Neurodegeneration: An Experience From a Tertiary Center
Tremor and Other Hyperkinetic Movements (TOHM) [ISSN: 2160-8288], a fully open access peer-reviewed journal, publishes clinical and scientific papers on tremor and hyperkinetic movements. TOHM is indexed in PubMed and PubMed Central. In contrast to other publications focusing on disorders of hypokinesia (i.e., mainly Parkinson’s disease), TOHM emphasizes the hyperkinetic movements, giving center stage to clinical observations and research in this area. Papers on Parkinson’s disease and related disorders will be considered if they relate to the hyperkinetic features of these diseases (e.g., tremor, dystonia, dyskinesias). The average turnaround time from submission to first decision is roughly 24 days (~3.5 weeks). The average turnaround time from acceptance to publication is 18 days (~2.5 weeks) with a median of 14 days (2 weeks). Tremor and Other Hyperkinetic Movements is indexed with the Web of Science Emerging Sources Citation Index. As of 2024, Tremor has a Journal Impact Factor of 2.5.
- 21 August 2024
- Published by Ubiquity Press, Ltd. in Tremor and Other Hyperkinetic Movements
- Vol. 14 (1) , 41
Open AccessThe Clinical, Radiological and Genetic Spectrum of PLA2G6-Associated Neurodegeneration: An Experience From a Tertiary Center
Tremor and Other Hyperkinetic Movements (TOHM) [ISSN: 2160-8288], a fully open access peer-reviewed journal, publishes clinical and scientific papers on tremor and hyperkinetic movements. TOHM is indexed in PubMed and PubMed Central. In contrast to other publications focusing on disorders of hypokinesia (i.e., mainly Parkinson’s disease), TOHM emphasizes the hyperkinetic movements, giving center stage to clinical observations and research in this area. Papers on Parkinson’s disease and related disorders will be considered if they relate to the hyperkinetic features of these diseases (e.g., tremor, dystonia, dyskinesias). The average turnaround time from submission to first decision is roughly 24 days (~3.5 weeks). The average turnaround time from acceptance to publication is 18 days (~2.5 weeks) with a median of 14 days (2 weeks). Tremor and Other Hyperkinetic Movements is indexed with the Web of Science Emerging Sources Citation Index. As of 2024, Tremor has a Journal Impact Factor of 2.5.
- 1 January 2024
- Published by Elsevier in Parkinsonism & Related Disorders
- Vol. 120, 105986
Clinical and genetic profile of patients with dystonia: An experience from a tertiary neurology center from India
- 1 January 2024
- Published by Elsevier in Parkinsonism & Related Disorders
- Vol. 120, 105986
Clinical and genetic profile of patients with dystonia: An experience from a tertiary neurology center from India
- Open Access
- 30 September 2023
- Published by The Korean Movement Disorder Society in Journal of Movement Disorders
- Vol. 16 (3) , 343-346
Dystonic Opisthotonus in Kufor-Rakeb Syndrome: Expanding the Phenotypic and Genotypic Spectrum
- 30 September 2023
- Published by The Korean Movement Disorder Society in Journal of Movement Disorders
- Vol. 16 (3) , 343-346
Open AccessDystonic Opisthotonus in Kufor-Rakeb Syndrome: Expanding the Phenotypic and Genotypic Spectrum
- Open Access
- 30 September 2023
- Published by The Korean Movement Disorder Society in Journal of Movement Disorders
- Vol. 16 (3) , 285-294
KMT2B-Related Dystonia in Indian Patients With Literature Review and Emphasis on Asian Cohort
ObjectiveaaMutations in the KMT2B gene have been identified in patients previously diagnosed with idiopathic dystonia. Literature on KMT2B-related dystonia is sparse in the Indian and Asian populations.MethodsaaWe report seven patients with KMT2B-related dystonia studied prospectively from May 2021 to September 2022. Patients underwent deep clinical phenotyping and genetic testing by whole-exome sequencing (WES). A systematic literature search was performed to identify the spectrum of previously published KMT2B-related disorders in the Asian subcontinent.ResultsaaThe seven identified patients with KMT2B-related dystonia had a median age at onset of four years. The majority experienced onset in the lower limbs (n = 5, 71.4%), with generalization at a median duration of 2 years. All patients except one had complex phenotypes manifesting as facial dysmorphism (n = 4), microcephaly (n = 3), developmental delay (n = 3), and short stature (n = 1). Magnetic resonance imaging (MRI) abnormalities were present in four cases. WES revealed novel mutations in the KMT2B gene in all patients except one. Compared to the largest cohort of patients with KMT2B-related disorders, the Asian cohort, comprising 42 patients, had a lower prevalence of female patients, facial dysmorphism, microcephaly, intellectual disability, and MRI abnormalities. Protein-truncating variants were more prevalent than missense variants. While microcephaly and short stature were more common in patients with missense mutations, facial dysmorphism was more common in patients with truncating variants. Deep brain stimulation, performed in 17 patients, had satisfactory outcomes.ConclusionaaThis is the largest series of patients with KMT2B-related disorders from India, further expanding the clinico-genotypic spectrum. The extended Asian cohort emphasizes the unique attributes of this part of the world.
- 30 September 2023
- Published by The Korean Movement Disorder Society in Journal of Movement Disorders
- Vol. 16 (3) , 285-294
Open AccessKMT2B-Related Dystonia in Indian Patients With Literature Review and Emphasis on Asian Cohort
ObjectiveaaMutations in the KMT2B gene have been identified in patients previously diagnosed with idiopathic dystonia. Literature on KMT2B-related dystonia is sparse in the Indian and Asian populations.MethodsaaWe report seven patients with KMT2B-related dystonia studied prospectively from May 2021 to September 2022. Patients underwent deep clinical phenotyping and genetic testing by whole-exome sequencing (WES). A systematic literature search was performed to identify the spectrum of previously published KMT2B-related disorders in the Asian subcontinent.ResultsaaThe seven identified patients with KMT2B-related dystonia had a median age at onset of four years. The majority experienced onset in the lower limbs (n = 5, 71.4%), with generalization at a median duration of 2 years. All patients except one had complex phenotypes manifesting as facial dysmorphism (n = 4), microcephaly (n = 3), developmental delay (n = 3), and short stature (n = 1). Magnetic resonance imaging (MRI) abnormalities were present in four cases. WES revealed novel mutations in the KMT2B gene in all patients except one. Compared to the largest cohort of patients with KMT2B-related disorders, the Asian cohort, comprising 42 patients, had a lower prevalence of female patients, facial dysmorphism, microcephaly, intellectual disability, and MRI abnormalities. Protein-truncating variants were more prevalent than missense variants. While microcephaly and short stature were more common in patients with missense mutations, facial dysmorphism was more common in patients with truncating variants. Deep brain stimulation, performed in 17 patients, had satisfactory outcomes.ConclusionaaThis is the largest series of patients with KMT2B-related disorders from India, further expanding the clinico-genotypic spectrum. The extended Asian cohort emphasizes the unique attributes of this part of the world.
- 25 July 2022
- Published by Wiley in Journal of Neuroendocrinology
- Vol. 34 (10) , e13185
Whole exome sequencing and transcript analysis discover a novel pathogenic splice site mutation in DCAF17 gene underlying Woodhouse‐Sakati syndrome.
Woodhouse‐Sakati syndrome (WSS) is an extremely rare multisystemic disorder with neuroendocrine dysfunctions. It is characterized by hypogonadism, alopecia, diabetes mellitus, intellectual disability and progressive extrapyramidal syndrome along with radiological features of small pituitary gland, progressive frontoparietal white matter changes and abnormal accumulation of iron on globus pallidus. WSS is caused by mutations in DCAF17 gene that encodes for DDB1 and CUL4 associated factor 17. In this study, we report a 17‐year‐old boy with clinical and radiological features of WSS including mild global developmental delay, mild intellectual disability, sensorineural hearing loss, progressive extrapyramidal syndrome, alopecia, hypogonadotropic hypogonadism and dysmorphic features. Whole exome sequencing analysis revealed a novel potentially pathogenic splice donor site variant (c.458+1G>T) on the intron 4 of DCAF17 gene. Transcript analysis revealed splicing ablation resulting in aberrant splicing of exons 3 and 5 and skipping of exon 4 (c.322_458del). This results in a frameshift and is predicted to cause premature termination of protein synthesis resulting in a protein product of length 120 amino acids (p.[Gly108Ilefs*14]). Our study identified a novel pathogenic variant causing WSS in a patient and expands the spectrum of clinical and genetic characteristics of patients with WSS.
- 25 July 2022
- Published by Wiley in Journal of Neuroendocrinology
- Vol. 34 (10) , e13185
Whole exome sequencing and transcript analysis discover a novel pathogenic splice site mutation in DCAF17 gene underlying Woodhouse‐Sakati syndrome.
Woodhouse‐Sakati syndrome (WSS) is an extremely rare multisystemic disorder with neuroendocrine dysfunctions. It is characterized by hypogonadism, alopecia, diabetes mellitus, intellectual disability and progressive extrapyramidal syndrome along with radiological features of small pituitary gland, progressive frontoparietal white matter changes and abnormal accumulation of iron on globus pallidus. WSS is caused by mutations in DCAF17 gene that encodes for DDB1 and CUL4 associated factor 17. In this study, we report a 17‐year‐old boy with clinical and radiological features of WSS including mild global developmental delay, mild intellectual disability, sensorineural hearing loss, progressive extrapyramidal syndrome, alopecia, hypogonadotropic hypogonadism and dysmorphic features. Whole exome sequencing analysis revealed a novel potentially pathogenic splice donor site variant (c.458+1G>T) on the intron 4 of DCAF17 gene. Transcript analysis revealed splicing ablation resulting in aberrant splicing of exons 3 and 5 and skipping of exon 4 (c.322_458del). This results in a frameshift and is predicted to cause premature termination of protein synthesis resulting in a protein product of length 120 amino acids (p.[Gly108Ilefs*14]). Our study identified a novel pathogenic variant causing WSS in a patient and expands the spectrum of clinical and genetic characteristics of patients with WSS.